Beam Therapeutics (BEAM) Stock Update
- Closing price (22 Oct 2026, 02:24 AM CET): USD 24.84, up 3.06 % from the previous close.
- Trading volume (last 24 h): USD 36.9 million.
- Shares outstanding: 100 million.
- Market capitalization: USD 2.4 billion.
- Price trend: The stock has declined 1.31 % since the previous month‑end.
- 200‑day simple moving average: USD 28.32.
- 52‑week range: Highest USD 38.26 (07 Jul 2026); lowest USD 20.23 (20 Nov 2025).
Peer Performance (last 24 h)
| Stock | Ticker | % Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Peabody Energy | BTU | –4.71 % | USD 22.44 | USD 2.9 bn | – |
| Penguin | PENG | –0.39 % | USD 58.38 | USD 2.9 bn | 21.92 |
| Kyndryl | KD | +4.59 % | USD 14.35 | USD 2.9 bn | 34.8 |
| Denali Therapeutics | DNLI | +4.93 % | USD 18.68 | USD 2.9 bn | – |
| Privia Health | PRVA | +2.18 % | USD 22.47 | USD 2.9 bn | 102.28 |
Company Overview
Beam Therapeutics Inc. is a biotechnology firm headquartered in Cambridge, United States, focused on DNA base‑editing technologies for therapeutic applications. The company is listed on the Nasdaq and serves customers primarily in the state of Massachusetts. Further information can be obtained from its website at www.beamtx.com .
